Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0CRHCH
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
ABBV-322
|
|||||
| Synonyms |
ABBV322; ABBV 322; Depatuxizumab S238C-PBD dimer
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Pleural mesothelioma [ICD11:2C26]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Antibody Name |
Depatuxizumab S238C
|
Antibody Info | ||||
| Antigen Name |
Epidermal growth factor receptor (EGFR)
|
Antigen Info | ||||
| Payload Name |
PBD dimer
|
Payload Info | ||||
| Therapeutic Target |
Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Mc-Val-Ala
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
General Information of The Activity Data Related to This ADC
Discovered Using Patient-derived Xenograft Model
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Patient-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 34.60% (Day 28) | Positive EGFR expression (EGFR+++/++) | ||
| Method Description |
For the PDX 14R091 and PDX MPM36 studies, mice received ABBV-322 (0.03 mg/kg) or control ADC (0.03 mg/kg) every 4 days, for a total of 12 treatments.
|
||||
| In Vivo Model | Malignant Mesothelioma PDX model (PDX: MPM36) | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 65.80% (Day 60) | Positive EGFR expression (EGFR+++/++) | ||
| Method Description |
For the PDX 14R091 and PDX MPM36 studies, mice received ABBV-322 (0.03 mg/kg) or control ADC (0.03 mg/kg) every 4 days, for a total of 12 treatments.
|
||||
| In Vivo Model | Malignant Mesothelioma PDX model (PDX: 14R091) | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 10.00 ug/mL - 35.00 ug/mL | Positive EGFR expression (EGFR+++/++) | ||
| Method Description |
Cells lines were plated at 1,000-3,000 cells per well in complete growth medium containing 10% FCS in 96-well plates and allowed to adhere overnight.
|
||||
| In Vitro Model | Pleural biphasic mesothelioma | MSTO-211H cells | CVCL_1430 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 10.00 ug/mL - 35.00 ug/mL | Positive EGFR expression (EGFR+++/++) | ||
| Method Description |
Cells lines were plated at 1,000-3,000 cells per well in complete growth medium containing 10% FCS in 96-well plates and allowed to adhere overnight.
|
||||
| In Vitro Model | Pleural mesothelioma | NCI-H28 cells | CVCL_1555 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 10.00 ug/mL - 35.00 ug/mL | Positive EGFR expression (EGFR+++/++) | ||
| Method Description |
Cells lines were plated at 1,000-3,000 cells per well in complete growth medium containing 10% FCS in 96-well plates and allowed to adhere overnight.
|
||||
| In Vitro Model | Pleural mesothelioma | NCI-H2052 cells | CVCL_1518 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 10.00 ug/mL - 35.00 ug/mL | Positive EGFR expression (EGFR+++/++) | ||
| Method Description |
Cells lines were plated at 1,000-3,000 cells per well in complete growth medium containing 10% FCS in 96-well plates and allowed to adhere overnight.
|
||||
| In Vitro Model | Pleural mesothelioma | NCI-H2052 cells | CVCL_1518 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.